Medomics Seeks to Raise up to $4M for Sequencing-Based Mitochondrial Disease Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Personalized medicine startup Medomics said this week that it is in discussions with various undisclosed entities to raise $3 million to $4 million to further develop and market its gene sequencing-based diagnostic test for mitochondrial diseases.

Medomics, based in Azusa, Calif., expects to receive a $1 million investment from an undisclosed corporate co-investor if it can raise $2 million to $3 million in financing from additional investors, Steve Sommer, president and founder of Medomics, told GenomeWeb Daily News.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.